Heralding a New Era of Episodic, Chronic and Refractory Migraine Management

PRO Tool

Measuring the burden of headache worldwide

The HALT indices and HURT questionnaire are products of the Global Campaign against Headache led by Lifting The Burden in official relations with the World Health Organization.

Headache-Attributed Lost Time (HALT) indices are a measure of burden for headache management in primary care.

Headache Under-Response to Treatment (HURT) index is a diagnostic diary, and an outcome measure specifically to guide follow-up in primary care.

Timothy J Steiner

Emeritus Professor of Medicine (Headache and Global Public Health) in the Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway

Professor Steiner is an academic physician and specialist in headache medicine. He trained first in physiology, and then in medicine at the University of London. Later he obtained Masters Degrees in law, in medical ethics and in business management.

He has worked in the field of headache medicine for 40 years. He is past-President of the European Headache Federation and past-General Secretary of the International Headache Society.

His principal research interests relate to public health aspects of headache. He is the founder of the UK-registered charity, Lifting The Burden, which operates in official relations with the World Health Organization. He is the architect and Director of the Global Campaign against Headache, which is conducted by Lifting The Burden as its principal activity.

English-language version

Also available in the following languages

  1. Steiner TJ, Lipton RB on behalf of Lifting The Burden: The Global Campaign against Headache. The Headache-Attributed Lost Time (HALT) Indices: measures of burden for clinical management and population-based research. J Headache Pain 2018; 19: 12.
  2. Steiner TJ, Buse DC, Al Jumah M et al, Lipton RB on behalf of Lifting The Burden: The Global Campaign against Headache. The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. J Headache Pain 2018; 19: 15.

We would like to thank all the translators who participated in the creation of this project.

France

  • Sylvie Chauvet, member, French Society for the Study of Migraine and Headache Disorders; French Society for the Study of Pain; and Swiss Society for the Study of Pain

Spain

  • Professor Miguel JA Láinez, Department of Neurology, University Clinic Hospital, Catholic University of Valencia, Valencia, Spain
  • Margy Farrington, lay advisor (no affiliation)

Portugal

  • Dr Raquel Gil-Gouveia, Department of Neurology, Hospital da Luz, Lisbon, Portugal
  • Dr Sofia Nunes Oliveira, Department of Neurology, Hospital da Luz, Lisbon, Portugal
  • Dr Martin Lautherbach, Department of Neurology, Hospital da Luz, Lisbon, Portugal
  • Dr Inês Brás Marques, Department of Neurology, Hospital da Luz, Lisbon, Portugal

Netherlands

  • Emile Couturier, Neurology Center Amsterdam, Amsterdam, The Netherlands
  • Andrés Sadde, lay advisor, Neurology Center Amsterdam, Amsterdam, The Netherlands

Turkey

  • Professor Derya Uluduz, Neurology Department, Cerrahpaşa School of Medicine, Istanbul University, Istanbul, Turkey
  • Dr Devrimsel Harika Ertem, Neurology Department, Cerrahpaşa School of Medicine, Istanbul University, Istanbul, Turkey

Russia

  • Vera Osipova, Neurological Research Department, Sechenov University and Moscow Research Clinical Centre for Neuropsychiatry; and University Headache Clinic, Moscow, Russian Federation
  • Nina Latisheva, Department of Neurology, Institute for Professional Education, I.M. Sechenov First Moscow State Medical University; and Alexander Vein Headache Clinic, Moscow, Russian Federation

Arabic

  • Dr Ali M Al Khathaami, King Abdulaziz Medical City, Riyadh; King Abdullah International Medical Research Centre, Riyadh; and King Saud Bin Abdulaziz University for Health Sciences, Riyadh
  • Dr Mohammed Al Jumah, King Saud Bin Abdulaziz University for Health Sciences, Riyadh; and Department of Neurosciences, King Fahad Medical City, MOH, Riyadh, Saudi Arabia

China (Mandarin)

  • Ruozhuo Liu, Department of Neurology, First Medical Center of Chinese PLA General Hospital, Beijing, PR China
  • Enchao Qiu, Department of Neurology, Fourth Medical Center of Chinese PLA General Hospital, Beijing, PR China

Japan

  • Mamoru Shibata, Department of Neurology, Keio University School of Medicine, Tokyo, Japan
  • Fumihiko Sakai, Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan
  • Yuko Saisho, Saitama Neuropsychiatric Institute, Saitama, Japan

Hindi

  • Professor Debashish Chowdhury, Department of Neurology, G B Pant Institute of Post Graduate Medical Education and Research (GIPMER), Delhi, India
  • Professor Anand Krishnan, Centre for Community Medicine, All India Institute of Medical Sciences (AIIMS), Delhi, India

Germany

  • Dr Charly Gaul, Migraine and Headache Clinic Königstein, Königstein im Taunus, Germany
  • Dr Heike Zimmermann-Timm, Migraine and Headache Clinic Königstein, Königstein im Taunus, Germany

This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.